{"disease":{"id":"indolent-non-hodgkin-s-lymphomas","name":"indolent non hodgkin s lymphomas"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01732926","title":"Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":475,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT01732913","title":"Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":295,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT02362035","title":"ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":161,"lead_sponsor_name":"Acerta Pharma BV","has_results":true}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}